Staging, Resectability, and Outcome in 225 Patients With Hilar Cholangiocarcinoma
By W. Jarnagin, Y. Fong, R. DeMatteo, Mithat Gonen, E. Burke, Jessica Bodniewicz, BS, Miranda Youssef, BA, D. Klimstra, L. Blumgart. Annals of Surgery, 2001
1,324 citations recorded by the source corpus.
Subfields: Hepatology, Pulmonary and Respiratory Medicine, Surgery
View Paper: https://www.semanticscholar.org/paper/926cb6fd4183b5f76f79d736477df271a85ee46e
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Surgery
Citations in the corpus
- One thousand fifty-six hepatectomies without mortality in 8 years. (2003, neutral): “Blood loss, mL 635 (15-8200) 578 (0-6650) 913 (80-3136) 459 (35-2000) 580 (17-2100)”
- Cholangiocarcinoma — evolving concepts and therapeutic strategies (2017, neutral): “Cholangiocarcinomas are aggressive tumours, and most patients have advancedstage disease at presen tation 6 .”
- Improvement in Perioperative Outcome After Hepatic Resection: Analysis of 1,803 Consecutive Cases Over the Past Decade (2002, background): “There were 15 central hepatecto- 1 Includes arthritis (27), history of DVT/PE (19), major depression (10), other endocrine disorders (9), chronic renal failure (8), parkinsonism (4), osteoporosis (4), tuberculosis (2), seizure disorder (2), Alzheimer’s disease, Turner’s syndrome, sarcoidosis, amyloi”